TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00948129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Undergo standard of care smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Undergo standard of care smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Undergo standard of care smoking cessation intervention
Study: NCT01624493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC105P
Description: BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
Study: NCT00948129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Undergo telephone based smoking cessation intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Undergo smoking cessation counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Undergo smoking cessation counseling
Study: NCT04012502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toxicities reduced treatment
Description: Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
Study: NCT01289275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Up to 5 proactive counseling sessions from California Smokers' Helpline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Up to 5 proactive counseling sessions from California Smokers' Helpline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Hospital Counseling
Description: All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Hospital Counseling
Description: All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Hospital Counseling
Description: All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Hospital Counseling
Description: All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
Study: NCT01610219

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification for Type 2 Diabetes Prevention
Description: Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition and Physical Activity
Description: This family based education program provided information on physical activity and healthy eating for parents and children.
Study: NCT00954629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: strontium chloride hexahydrate
Description: Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
Study: NCT01040091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine (FTC)
Description: 200 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: 300 mg once a day
Study: NCT06793878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living in Families With Emotions
Description: This is an 8-week group-based psychosocial intervention teaching adolescents how to recognize their feelings, manage them, and talk about emotions through group discussions, live exercises, and games. The adolescents' caregivers are also provided with the same information, through two live sessions.
Study: NCT01040091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz (EFV)
Description: 600 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: 200 mg emtricitabine + 300 mg TDF once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: 200 mg emtricitabine + 300 mg TDF once a day
Study: NCT03090516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dispersible tablets
Description: Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Arm A：Aricept 5mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dispersible tablets and Donepezil
Description: Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
Study: NCT04378998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
Study: NCT03397433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Technology physician assist
Description: The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
Study: NCT03350035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ganaxolone active
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo, non-active
Description: IV
Study: NCT02005159

Intervention type: OTHER
Intervention: Microbiological studies
Study: NCT01948765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenon and propofol
Description: xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: propofol target controlled infusion (target 1.5-2.5µg/ml)
Study: NCT01545934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
Study: NCT04547335

Intervention type: DRUG
Intervention: Voriconazole
Description: This is an observational study and only the patients already on voriconazole treatment will be included in the study.
Study: NCT03654404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention
Description: Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
Study: NCT00649272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride Extended-Release Tablets, 15 mg
Description: 15mg, single dose fasting
Study: NCT03215758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAW039
Description: QAW039 once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT05659407

Intervention type: DRUG
Intervention: Belimumab in SLE patients / Rituximab in RA patients
Description: Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.

Intervention type: DRUG
Intervention: Belimumab in SLE patients / Rituximab in RA patients
Description: Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
Study: NCT02681211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
Study: NCT02684877

Intervention type: OTHER
Intervention: Questionnaire
Study: NCT04225052

Intervention type: DRUG
Group type: OTHER
Intervention: YHP1903
Description: YHP1903 Tab. 1mg

Intervention type: DRUG
Group type: OTHER
Intervention: YHP1903
Description: YHP1903 Tab. 1mg

Intervention type: DRUG
Group type: OTHER
Intervention: Champix
Description: Comparator Champix Tab. 1mg

Intervention type: DRUG
Group type: OTHER
Intervention: Champix
Description: Comparator Champix Tab. 1mg
Study: NCT03199326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
Study: NCT02912494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Study: NCT00733837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonspecific, Innocuous, Mechanoreceptor Stimulation
Description: A custom device will be used to provide light manual cervical traction
Study: NCT02038140

Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer Trabecular Metal Total Ankle System
Description: Primary or revision total ankle replacement
Study: NCT04187508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8154 nebulizer suspension, 20 mg/mL
Description: Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
Study: NCT03655691

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
Study: NCT00227695

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: comparing two maintenance schedules of Rituximab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: comparing two maintenance schedules of Rituximab
Study: NCT00404677

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: deep inhalation
Description: deep inhalation is comprised of an inhalation manoeuver from FRC to TLC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: deep inhalation
Description: deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
Study: NCT04220684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT04187508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
Study: NCT01186042

Intervention type: OTHER
Intervention: Observational
Description: No intervention
Study: NCT00223808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-Low
Description: 1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
Study: NCT04220684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Description: Given via infusion
Study: NCT00223808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-High
Description: 2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
Study: NCT06798935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich stroma
Description: Autologous platelet-rich stroma, which is the combined product of stromal vascular fraction and platelet-rich plasma
Study: NCT02172573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pramipexole
Study: NCT02681211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 0.5mg/kg, max 30mg
Description: If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide 0.1 mg/kg, max 10mg
Description: If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine 1mg/kg, max 50mg
Description: If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline fluid bolus 20mL/kg, max 1000mL
Description: If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~1. Ketorolac 0.5mg/kg, max 30mg~2. Metoclopramide 0.1 mg/kg, max 10mg~3. Diphenhydramine 1mg/kg, max 50mg~4. Normal saline fluid bolus 20mL/kg, max 1000mL
Study: NCT01125371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized brief alcohol intervention + IVR booster calls
Description: 1) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized brief alcohol intervention
Description: Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
Study: NCT02194348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS - in single rising doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04446546

Intervention type: PROCEDURE
Intervention: Vascular access by pass using a cold stored venous allograft
Description: Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft
Study: NCT02458820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DSA EEG
Description: Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
Study: NCT00225173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 IV w 1, 5, 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
Study: NCT00649272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Extended-release tablets, 15 mg
Description: 15mg, single dose fasting
Study: NCT03667833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder brace
Description: Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder brace
Description: Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
Study: NCT00225173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Bleomycin 5 u/m2 IV w 2,4,6,8,10,12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2 IV w 13,15,17,19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25 mg/m2 IV w 13,15,17,19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 40 mg/m2 PO qod w 1-10, taper
Study: NCT03818828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTAX01
Description: TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Profore Compression Therapy
Description: Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cadexomer Iodine dressing
Description: During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
Study: NCT02172573

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo bromocriptine
Study: NCT04022226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Induction agent that suppresses infra-slow waves